How We Use BTK Inhibitors to Treat CLL, MCL, MZL, and Waldenström Macroglobulinemia
  • CME
  • CE

Review the most clinically relevant BTK inhibitor data across multiple B-cell malignancies with this set of expert commentaries, including advances in CLL, MCL, MZL, and Waldenström macroglobulinemia.
Farrukh T. Awan, MD
Ian W. Flinn, MD, PhD
person default
Prashant Kapoor, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 29, 2020 Expiration: May 28, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal, individualized therapeutic strategies for patients with MCL, MZL, CLL/SLL, and WM considering recent practice changing clinical trial results
  • Consider existing and emerging clinical research data evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) in the formulation of therapeutic recommendations for patients with MCL, MZL, CLL/SLL, and WM
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support quality of life and continuation of treatment
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options, LLC.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by an educational grant from
Pharmacyclics LLC, An AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Farrukh T. Awan, MD

Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program

Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh Awan, MD, MS, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Blueprint, Celgene, Dava Oncology, Genentech, Gilead Sciences, Janssen, Karyopharm, Kite, MEI Pharma, Pharmacyclics, and Sunesis.
Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees form AbbVie, Seattle Genetics, TG Therapeutics, and Verastem; that he has received funds for research support from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Merck, Morphosys, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Takeda, Teva, TG Therapeutics, Unum, and Verastem; and that he and his spouse have less than 5% ownership interest in Johnson & Johnson.
Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology
Consultant
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Prashant Kapoor, MD, has disclosed that he has received consulting fees from Cellectar, Karyopharm, Pharmacyclics, and Sanofi; funds for research support from AbbVie, Amgen, GlaxoSmithKline, Sanofi, and Takeda; and fees for non-CME/CE services from Sanofi.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

The Annenberg planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with MCL, MZL, CLL/SLL, and WM.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in leveraging BTK inhibitors (and emerging BTK inhibitor–based combinations) to individualize clinical management of patients with mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenström macroglobulinemia.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-20-047-H01-P. This program is designated for up to 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit.

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 29, 2020, through May 28, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Living slideset on optimal management of CLL during the COVID-19 pandemic will be continually up-to-date as the situation evolves and new data emerge

Jacqueline Barrientos, MD, MS Nicole Lamanna, MD John Pagel Headshot John Pagel, MD, PhD person default Jacob D. Soumerai, MD Released: July 2, 2020

Gain key clinical insights quickly with this short slideset from CCO on CAR T-cell therapy for hematologic malignancies.

Michael R. Bishop, MD Daniel J. DeAngelo, MD, PhD Noopur Raje, MD Released: June 30, 2020

From Clinical Care Options (CCO), read an expert commentary on ibrutinib plus rituximab for frontline CLL treatment

Anthony Mato, MD Released: June 26, 2020

In this slideset from Clinical Care Options, Jeremy S. Abramson, MD, MMSc and Christopher R. Flowers, MD, MS highlight key data on the optimal use of BTK inhibitors

Jeremy S. Abramson, MD, MMSc Christopher R. Flowers, MD, MS Released: June 26, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?